代谢相关脂肪性肝病的治疗进展
Progress in the Treatment of Metabolism-Related Fatty Liver Disease
摘要: 代谢相关脂肪性肝病(MAFLD)的发病率逐年增加，成为目前全球最常见的慢性肝脏疾病。本文总结了国内外最新指南及研究，旨在探讨当前MAFLD的治疗进展，主要涉及生活方式管理、药物治疗、减重手术、肝移植等多学科的治疗，其原则包括：一是针对肥胖和代谢性疾病进行的生活方式管理，二是针对不同代谢疾病和病理类型进行的个体化药物治疗和外科手术等。前者包含调整饮食结构、减轻体重、适量运动以及对血压、血脂、血糖异常等指标进行控制；后者包括二甲双胍、维生素C和E、利拉鲁肽、吡格列酮、他汀类药物及减重手术、肝移植等。但对于MAFLD患者来说，无论伴或不伴有肥胖，保持健康饮食和运动仍然是防治的根本。
Abstract: The incidence of metabolism-related fatty liver disease (MAFLD) is increasing year by year and has become the most common chronic liver disease in the world. This paper summarizes the latest guidelines and research at home and abroad, explores the current MAFLD treatment progress, mainly involving lifestyle management, drug therapy, weight-loss surgery, liver transplantation, such as multi-disciplinary collaboration, the therapeutic principles include: one is to control man-agement for obesity and metabolic disease, the second is according to different pathological types of individualized drug therapy and surgery, etc. The former includes adjustment of diet, weight loss, moderate exercise and control of blood pressure, blood lipid, blood sugar and other indicators. The latter include metformin, vitamins C and E, liraglutide, pioglitazone, statins, bariatric surgery, liver transplantation, etc. However, for patients with MAFLD, maintaining a healthy diet and exercise are still essential for prevention and treatment, with or without obesity.
文章引用：李红红, 沈小雅, 郑惠, 延照, 张永莉. 代谢相关脂肪性肝病的治疗进展[J]. 临床医学进展, 2022, 12(9): 8647-8654. https://doi.org/10.12677/ACM.2022.1291249

参考文献

[1] 万燕萍, 马雄, 王炳元, 等. 非酒精性脂肪性肝病防治指南(2018年更新版) [J]. 临床肝胆杂志, 2018, 34(5): 947-957.
[2] Eslam, M., Sarin, S.K., Wong, V.W., et al. (2020) The Asian Pacific Association for the Study of the Liver Clinical Practice Guidelines for the Diagnosis and Management of Metabolic Associated Fatty Liver Disease. Hepatology International, 14, 889-919. [Google Scholar] [CrossRef] [PubMed]
[3] 常彬霞, 李保森, 邹正升. 《2016年欧洲肝病学会、欧洲糖尿病学会和欧洲肥胖学会临床实践指南: 非酒精性脂肪性肝病》摘译[J]. 临床肝胆病杂志, 2016, 32(8): 1450-1454.
[4] 郑海兰, 李凡, 丁维, 等. 中性粒细胞/淋巴细胞比值与2型糖尿病合并非酒精性脂肪肝的相关性分析[J]. 安徽医学, 2020, 41(5): 562-566.
[5] Younossi, Z.M., Koenig, A.B., Ab-delatif, D., et al. (2016) Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Preva-lence, Incidence, and Outcomes. Hepatology, 64, 73-84. [Google Scholar] [CrossRef] [PubMed]
[6] Sookoian, S. and Pirola, C.J. (2019) Review Article: Shared Disease Mechanisms between Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome—Translating Knowledge from Sys-tems Biology to the Bedside. Alimentary Pharmacology & Therapeutics, 49, 516-527. [Google Scholar] [CrossRef] [PubMed]
[7] Zelber-Sagi, S., Nitzan-Kaluski, D., Goldsmith, R., et al. (2017) Long-Term Nutritional Intake and the Risk for Non-Alcoholic Fatty Liver Disease (NAFLD): A Population Based Study. Journal of Hepatology, 47, 711-717. [Google Scholar] [CrossRef] [PubMed]
[8] 刘静, 柳银兰, 杨文君, 等. 高脂高果糖饮食诱导非酒精性脂肪性肝炎小鼠模型的建立和鉴定[J]. 中华肝脏病杂志, 2014, 22(6): 445-450.
[9] Ristic-Medic, D., Kovacic, M., Takic, M., et al. (2020) Calorie-Restricted Mediterranean and Low-Fat Diets Affect Fatty Acid Status in Individuals with Nonalcoholic Fatty Liver Disease. Nutrients, 13, Article No. 15. [Google Scholar] [CrossRef] [PubMed]
[10] Ma, Y., Yang, W., Simon, T.G., et al. (2019) Dietary Patterns and Risk of Hepatocellular Carcinoma among U.S. Men and Women. Hepatology, 70, 577-586. [Google Scholar] [CrossRef] [PubMed]
[11] Torres, L.F., Cogliati, B. and Otton, R. (2019) Green Tea Prevents NAFLD by Modulation of miR-34a and miR-194 Expression in a High-Fat Diet Mouse Model. Oxidative Medicine and Cellular Longevity, 2019, Article ID: 4168380. [Google Scholar] [CrossRef] [PubMed]
[12] Yuichiro, E., Yochiro, K., Hideyuki, H., et al. (2015) Pilot Study of Li-raglutide Effects in Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease with Glucose Intolerance in Japanese Patients (LEAN-J). Hepatology Research, 45, 269-278. [Google Scholar] [CrossRef] [PubMed]
[13] 肖倩倩, 王梦雨, 范建高. 亚太肝病研究学会代谢相关脂肪性肝病临床诊疗指南(治疗部分)简介[J]. 临床肝胆病杂志, 2021, 37(1): 41-45.
[14] Golden, S.H., Brown, A., Cauley, J.A., et al. (2012) Health Disparities in Endocrine Disor-ders: Biological, Clinical, and Nonclinical Factors—An Endocrine Society Scientific Statement. The Journal of Clinical Endocrinology & Metabolism, 9, E1579-E1639. [Google Scholar] [CrossRef] [PubMed]
[15] Park, J.H., Kim, J.Y., Kim, S.H., et al. (2020) A Latent Class Analysis of Dietary Behaviours Associated with Metabolic Syndrome: A Retro-spective Observational Cross-Sectional Study. Nutrition Journal, 19, Article No. 116. [Google Scholar] [CrossRef] [PubMed]
[16] Miller, E.F. (2020) Nutrition Management Strategies for Nonal-coholic Fatty Liver Disease: Treatment and Prevention. Clinical Liver Disease, 15, 144-148. [Google Scholar] [CrossRef] [PubMed]
[17] Younossi, Z.M. (2019) Non-Alcoholic Fatty Liver Disease—A Global Public Health Perspective. Journal of Hepatology, 70, 531-544. [Google Scholar] [CrossRef] [PubMed]
[18] Bifari, F., Manfrini, R., Dei, C.M., et al. (2018) Multiple Target Tissue Effects of GLP-1 Analogues on Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). Pharmacological Research, 137, 219-229. [Google Scholar] [CrossRef] [PubMed]
[19] Ivancovsky-Wajcman, D., Fliss-Isakov, N., Salomone, F., et al. (2019) Dietary Vitamin E and C Intake Is Inversely Associated with the Severity of Nonalcoholic Fatty Liver Disease. Digestive and Liver Disease, 51, 1698-1705. [Google Scholar] [CrossRef] [PubMed]
[20] Bril, F., Biernacki, D.M., Kalavalapalli, S., et al. (2019) Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care, 42, 1481-1488. [Google Scholar] [CrossRef] [PubMed]
[21] Vos, M.B., Abrams, S.H., Barlow, S.E., et al. (2017) NASPGHAN Clini-cal Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommenda-tions from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). Journal of Pediatric Gastroenterology and Nutrition, 64, 319-334. [Google Scholar] [CrossRef] 
[22] Cusi, K., Orsak, B., Bril, F., et al. (2016) Long-Term Pioglitazone Treatment for Patients with Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Annals of Internal Medicine, 165, 305-315. [Google Scholar] [CrossRef] 
[23] Majzoub, A.M., Nayfeh, T., Barnard, A., et al. (2021) Systematic Review with Network Meta-Analysis: Comparative Efficacy of Pharmacologic Therapies for Fibrosis Improvement and Resolu-tion of NASH. Alimentary Pharmacology & Therapeutics, 54, 880-889. [Google Scholar] [CrossRef] [PubMed]
[24] Cheen, A.J. (2018) Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. Circulation Research, 122, 1439-1459. [Google Scholar] [CrossRef] 
[25] Smati, S., Canivet, C.M., Boursier, J., et al. (2021) An-ti-Diabetic Drugs and NASH: From Current Options to Promising Perspectives. Expert Opinion on Investigational Drugs, 30, 813-825. [Google Scholar] [CrossRef] [PubMed]
[26] Rakipovski, G., Rolin, B., Nohr, J., et al. (2018) The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That In-cludes Inflammatory Pathways. JACC: Basic to Translational Science, 3, 844-857. [Google Scholar] [CrossRef] [PubMed]
[27] Matikainen, N., Soderlund, S., Bjornson, E., et al. (2019) Lirag-lutide Treatment Improves Postprandial Lipid Metabolism and Cardiometabolic Risk Factors in Humans with Adequately Controlled Type 2 Diabetes: A Single-Centre Randomized Controlled Study. Diabetes, Obesity and Metabolism, 21, 84-94. [Google Scholar] [CrossRef] [PubMed]
[28] Cho, K.Y., Nakamura, A., Omori, K., et al. (2021) Favorable Effect of Sodium-Glucose Cotransporter 2 Inhibitor, Dapagliflozin, on Non-Alcoholic Fatty Liver Disease Compared with Pioglitazone. Journal of Diabetes Investigation, 12, 1272-1277. [Google Scholar] [CrossRef] [PubMed]
[29] Mantovani, A., Petracca, G., Csermely, A., et al. (2020) Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. Metabolites, 11, Article No. 22. [Google Scholar] [CrossRef] [PubMed]
[30] Han, T., Fan, Y., Gao, J., et al. (2021) Sodium Glucose Cotrans-porter 2 Inhibitor Dapagliflozin Depressed Adiposity and Ameliorated Hepatic Steatosis in High-Fat Diet Induced Obese Mice. Adipocyte, 10, 446-455. [Google Scholar] [CrossRef] [PubMed]
[31] Luo, J., Sun, P., Wang, Y., et al. (2021) Dapagliflozin At-tenuates Steatosis in Livers of High-Fat Diet-Induced Mice and Oleic Acid-Treated L02 Cells via Regulating AMPK/mTOR Pathway. European Journal of Pharmacology, 907, Article ID: 174304. [Google Scholar] [CrossRef] [PubMed]
[32] Yuichiro Yshino, T., Mamoru, Y., et al. (2017) Atorvastatin Reduces Cardiac and Adipose Tissue Inflammation in Rats with Metabolic Syndrome. International Journal of Cardiol-ogy, 240, 332-338. [Google Scholar] [CrossRef] [PubMed]
[33] 胥媚, 张铭烜, 张倩, 等. 减重手术与多种健康相关结局: 一项伞状评价[J]. 中国全科医学, 2021, 24(29): 3742-3750.
[34] Kwong, A.J., Devuni, D., Wang, C., et al. (2020) Outcomes of Liver Transplantation among Older Recipients with Non-Alcoholic Steatohepatitis in a Large Multicenter U.S. Cohort (REALT). Liver Transplantation, 26, 1492-1503. [Google Scholar] [CrossRef] [PubMed]
[35] Alvarez, C.S., Graubard, B.I., Thistle, J.E., et al. (2020) Attributable Fractions of Nonalcoholic Fatty Liver Disease for Mortality in the United States: Results from the Third National Health and Nutri-tion Examination Survey with 27 Years of Follow-Up. Hepatology, 72, 430-440. [Google Scholar] [CrossRef] [PubMed]
[36] Chalasani, N., Younossi, Z., Lavine, J.E., et al. (2018) The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology, 67, 328-357. [Google Scholar] [CrossRef] [PubMed]

为你推荐